Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biofrontera Inc

0.7115
+0.109918.27%
Volume:1.09M
Turnover:758.28K
Market Cap:6.72M
PE:-0.42
High:0.7550
Open:0.5914
Low:0.5914
Close:0.6016
Loading ...

Company Profile

Company Name:
Biofrontera Inc
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
93
Office Location:
120 Presidential Way,Suite 330,Woburn,Massachusetts,United States
Zip Code:
01801
Fax:
- -
Introduction:
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Directors

Name
Position
Hermann Lubbert
Chief Executive Officer and Chairman of the Board
Beth J. Hoffman
Director
Heikki Lanckriet
Director
John J. Borer
Director
Kevin D. Weber
Director

Shareholders

Name
Position
Hermann Lubbert
Chief Executive Officer and Chairman of the Board
Eugene Fredrick Leffler, III
Chief Financial Officer